drugset / Trial / NCT04718584
the Efficacy and Safety of LDP in Patients With Urinary and Male Genital Tumors
Phase 2
Completed
27 enrolled
Dragonboat Biopharmaceutical Company Limited
Fudan University · collab
NaSingle-groupOpen-labelTreatment
Summary
This is a single-arm,open, multicenter, phase II clinical study of the efficacy and safety of human anti-PD-L1 monoclonal antibody Injection (LDP) in the treatment of urinary and male genital tumors.
Timeline
- Start
- 2020-09-11
- Primary completion
- 2024-02-27
- Completion
- 2024-02-27
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | LDP | Monoclonal antibody | 10 mg/kg | Intravenous |